Custom-Made cancer vaccine shows promise in early trial

NCT ID NCT06614140

Completed Disease control Sponsor: Seqker Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This completed phase I/IIb trial tested a personalized vaccine made from each patient's unique tumor mutations. Eight adults with advanced solid tumors or high recurrence risk received the vaccine alongside an immune booster and later checkpoint inhibitors. The goal was to see if the vaccine is safe and can trigger an immune response against their cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: personalized neoantigen peptide vaccine with Poly-ICLC and checkpoint inhibitors
What this could lead to: If successful, this could point toward a personalized treatment that trains the immune system to attack a patient's specific cancer, potentially controlling tumor growth or reducing recurrence risk.
What could go wrong: This is a very early, small trial with only 8 participants, so results may not apply to all patients. The vaccine is personalized and complex, and it may not work for everyone or could cause side effects from immune activation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER SOLID TUMOR, ADULT

Contacts and locations

Locations

Vejthani Hospital

Bangkok, 10240, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.